Lars Andersen (Aarhus, Denmark) presents the VAM-IHCA trial on June 15th at the Critical Care Reviews Meeting 2022, in Titanic Belfast. The VAM-IHCA trial investigates the combination of vasopressin and methylprednisolone in in-hospital cardiac arrest. Chris Seymour (Pittsburgh, USA) delivers an editorial after the trial presentation. The session is chaired by Catriona Kelly (Dublin, Ireland).
Nick Crombie (Birmingham, England) presents the RePHILL trial, comparing pre-hospital administration of saline with blood products in patients with trauma-related haemorrhagic shock. Liz Wilcox (Toronto, Canada) delivers an editorial. The session is chaired by Catriona Kelly (Dublin, Ireland).
Derek Russell (Birmingham, USA) and Jon Casey (Nashville, USA) presents the results of the PREPARE II trial, investigating fluid bolus therapy for the prevention of cardiovascular collapse during emergency intubation. Anthony Gordon (London, England) delivers an editorial, which is followed by a panel discussion including Lennie Derde (Utrecht, the Netherlands), Andrew Althouse (Pittsburgh, USA), Elizabeth Wilcox (Toronto, Canada) and Lars Andersen (Aarhous, Denmark). The session is chaired by Chris Seymour from the USA. PREPARE II was simultaneously published in JAMA.
Drs Padmanabhan Ramnarayan and Paul Mouncey (both London) present the results of the FIRST-ABC trial, comparing high-flow nasal cannulae therapy with CPAP in acute ill children with respiratory failure, at the Critical Care Reviews Meeting 2022. Dr Srinivas Murthy (Vancouver) delivers an editorial, which is followed by a panel discussion including Profs Kathryn Maitland (Kalifi), John Marshall (Toronto) and Marion Campbell (Aberdeen). The session is chaired by Prof Howard Bauchner.
Rob Mac Sweeney (Belfast, Northern Ireland) hosts a panel discussion including Prof Paul Checchia (Houston, USA), Prof Wes Diddle (Washington DC, USA), Prof Ranjit Lall (Coventry, England), Prof Kathy Rowan (London, England), as well as the NITRIC trial chief investigator Luregn Schlapbach (Zurich, Switzerland) and editorialist Prof Mark Peters (London, England)
Dr Bronwen Connolly asks cheif investigator Luregn Schlapbach questions from the viewers during the livestream of the NITRIC trial results
Prof Mark Peters, from Great Ormond Street Hospital, delivers an editorial on the NITRIC trial, investigating nitric oxide during cardiac surgery for children with congenital cardiac disease. The chief investigator for the trial Assoc Prof Luregn Schlapbach replies.
Assoc Prof Luregn Schlapbach (Zurich, Switzerland) presents the results of the NITRIC trial, investigating nitric oxide during cardiac surgery for children with congenital cardiac disease.
Rob Mac Sweeney hosts a panel discussion on the results of the FIRST ABC trial, comparing HFNO with CPAP in recently extubated children. The panelists are Martha A.Q. Curley (Philadelphia), Christopher M. Horvat (Pittsburgh), Martin Kneyber (Groningen), and David Harrison (London). They are joined by Padmanabhan Ramnarayan (chief investigator), Alvin Richards-Belle (trial manager) and Adrienne Randolph (editorialist).
Chris Nutt (Belfast) asks the chief investigator of the FIRST-ABC trial Padmanabhan Ramnarayan (London) questions from the viewers during the livestream presentation of the trial results.
Dr Padmanabhan Ramnarayan (London) and Mr Alvin Richards-Belle (London) present the results of the FIRST-ABC (Step Down) trial, comparing high flow nasal oxygen with continuous positive airway pressure in recently extubated children.
Pär Johansson from Copenhagen joins Rob Mac Sweeney to discuss the fascinating phase II COMBAT-COVID trial, investigating prostacyclin in intubated patients with COVID-19 and severe
endotheliopathy. The trial was published in the American Journal of Respiratory and Critical Care Medicine in November 2021.
Naomi Hammond and Simon Finfer join Rob Mac Sweeney to discuss the reaction of the critical care community to the presentation and publication of both the PLUS trial and the systematic review and meta analysis comparing balanced solutions with 0.9% saline in the critically ill.